BMRN250117P60000
- 0.40
- 0.000.00%
Biomarin Pharmaceutical Newsroom
Biomarin Pharmaceutical Analyst Ratings
BofA Securities Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $101
J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
Jefferies Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $122
Jefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research
Biomarin Pharmaceutical Analyst Ratings
Wolfe Research Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $95
Wedbush Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $94
Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $86
Oppenheimer Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $78 to $122
BioMarin Pharmaceutical Price Target Maintained With a $80.00/Share by RBC Capital
BioMarin Pharmaceutical Is Maintained at Outperform by Evercore ISI Group
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $78 to $122
Baird Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $65
Biomarin Pharmaceutical Analyst Ratings
BMO Capital Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $115
BioMarin Pharmaceutical: Strong Financial Outlook and Strategic Positioning Justify Buy Rating